Economic Valuation for Cost–Benefit Analysis of Health Risk Reduction in Drinking Water Systems by Bergion, Viktor et al.
Economic Valuation for Cost–Benefit Analysis of Health Risk
Reduction in Drinking Water Systems
Downloaded from: https://research.chalmers.se, 2020-04-24 15:17 UTC
Citation for the original published paper (version of record):
Bergion, V., Lindhe, A., Sokolova, E. et al (2018)
Economic Valuation for Cost–Benefit Analysis of Health Risk Reduction in Drinking Water Systems
Exposure and Health, 12(1): 99-110
http://dx.doi.org/10.1007/s12403-018-00291-8
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Vol.:(0123456789) 
Exposure and Health (2020) 12:99–110 
https://doi.org/10.1007/s12403-018-00291-8
ORIGINAL PAPER
Economic Valuation for Cost–Benefit Analysis of Health Risk Reduction 
in Drinking Water Systems
Viktor Bergion1  · Andreas Lindhe1  · Ekaterina Sokolova1  · Lars Rosén1 
Received: 12 September 2018 / Revised: 7 December 2018 / Accepted: 10 December 2018 / Published online: 20 December 2018 
© The Author(s) 2018
Abstract
Microbial risk mitigation measures in drinking water systems aiming at preventing gastrointestinal disease can provide 
substantial societal health benefits if implemented properly. However, the procedure of including and monetising the health 
benefits in cost–benefit analysis (CBA) has been somewhat scattered and inconsistent in the literature, and there is a need 
for a comparison of available methods. First, through a literature review, we identified the methods to include health benefits 
in decision support and to monetise these benefits in CBA. Second, we applied the identified health valuation methods in 
a case study. In the case study, we investigated if changing the health valuation method could change the rank order of the 
decision alternatives’ net present values. In the case study a risk-based decision model that combined quantitative microbial 
risk assessment and CBA was used. Seven health valuation methods were identified, each of them including different aspects 
of health benefits. The results of the case study showed that the choice of the health valuation method can change the rank 
order of decision alternatives with respect to their net present values. These results highlight the importance of choosing an 
appropriate health valuation method for the specific application. Although this study focused on the drinking water context, 
the identified health valuation methods can be applied in any decision support context, provided that input in terms of the 
health risk reduction is available.
Keywords Decision support · Health benefits · Microbial risk · Quality adjusted life year (QALY) · Quantitative microbial 
risk assessment (QMRA) · Risk mitigation
Introduction
To improve society and human health, the United Nations 
has adopted 17 sustainable development goals, of which sev-
eral concern water and sanitation related to gastrointestinal 
disease. Gastrointestinal disease is one of the major causes 
of negative health effects globally (WHO 2008). In Sweden, 
several large waterborne outbreaks of gastrointestinal dis-
ease have taken place during the last decades (PHAS 2011) 
causing substantial costs to society (Lindberg et al. 2011). 
Hence, mitigation of microbial health risks in order to avoid 
gastrointestinal disease is of value to society. Risk manage-
ment is also essential for water utilities to provide safe drink-
ing water. Cost–benefit analysis (CBA), increasingly applied 
to support decision makers, is one aid to help maximise risk 
reduction when allocating scarce societal resources. How-
ever, the procedures for monetising and including health 
benefits in CBA have been somewhat scattered and incon-
sistent. There is a need for a comparison of different health 
valuation methods. In this paper, we identify and compare 
methods for valuation of health benefits in the context of 
microbial health risk reduction in drinking water systems. 
We also apply the identified methods in a case study to illus-
trate their effects on decision support.
Societal resources are limited, and it is important to use 
adequate decision support when choosing the risk mitiga-
tion measures to implement. In our earlier study (Bergion 
et al. 2018), a decision model was developed to facilitate 
the comparison and evaluation of microbial health risk 
reduction measures in drinking water systems. The deci-
sion model combines quantitative microbial risk assessment 
(QMRA) and CBA. Through combining these two methods, 
societal benefits from health risk reduction measures can be 
included in decision support in a structured and transparent 
manner. QMRA (Haas et al. 2014) is an established concept 
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for estimating microbial risk and has been applied to drink-
ing water systems (e.g. Schijven et al. 2011; WHO 2016). 
In the decision model (Bergion et al. 2018), the health risk 
reductions are quantified using QMRA. In the CBA, these 
health risk reductions are monetised into health benefits. The 
benefits are compared to the costs of the mitigation measure, 
using the net present value (NPV), to evaluate the societal 
profitability of each risk reduction measure. The NPV is the 
sum of discounted costs and benefits, using a social discount 
rate in order to account for time preferences and productiv-
ity of capital (Hanley and Barbier 2009). The NPV can also 
be used to compare different risk reduction measures with 
each other. Adopting a CBA perspective provides a societal 
perspective by also including external effects (e.g. environ-
mental costs).
Different aspects of health benefits related to environmen-
tal decision making are illustrated in Fig. 1. The horizontal 
cells in Fig. 1 divide the health benefits into the following 
aspects: cost of illness in terms of medical costs; cost of 
illness due to loss of production; cost of averting behaviour 
(costs that occur due to investments or behaviour that aims 
for avoiding risks) and intangible costs (costs that relate to 
effects that are not possible to monetise due to the absence 
of a market value). The vertical cells in Fig. 1 divide the 
aspects between costs that are borne by the society and costs 
that are borne by individuals. This division of aspects facili-
tates comparison and helps map the different health valua-
tion methods, since the cells that are included in each health 
valuation method differ.
In a risk management framework, one approach to 
quantify health risk reduction is through the probability 
of illness. Several states of illness can be described. In a 
drinking water context focusing on pathogens causing gas-
trointestinal disease, these states of illness can be divided 
into mild cases (watery diarrhoea/loose stool, nausea and 
acute vomiting, intestinal cramps), severe cases (visits to 
physician, hospitalisation), secondary (sequelae) conditions 
(irritable bowel syndrome, Guillain-Barré syndrome, reac-
tive arthritis, etc.) and deaths (Rice et al. 2006). Another 
approach to quantify health risk reduction is through health 
adjusted life years (HALYs). HALYs are health metrics, e.g. 
disability adjusted life years (DALYs) and quality adjusted 
life years (QALYs), that include both the severity of the ill-
ness accounting for all possible states of illnesses, including 
death, and the duration of the illness, into one single metric. 
DALYs combine the life years lived with disability and the 
years of life lost. QALYs can in general terms be described 
as the inverse of DALYs (1 DALY ≈ − 1 QALY), but instead 
of measuring disability, QALYs estimate the quality of life. 
The value of health risk reduction in, for example, water 
resource management can be estimated through economic 
valuation (Andersson et al. 2016; Birol et al. 2006). The 
economic valuation can be performed using willingness to 
pay (WTP) studies, such as stated preferences (e.g. contin-
gent valuation methods, choice experiment) and revealed 
preferences (e.g. cost of illness (COI), averted expenditure).
Hofstetter and Hammitt (2002) described WTP, DALYs 
and QALYs as health metrics for environmental decision 
support. However, the different metrics include different 
cells in Fig. 1. Moreover, the WTP is a monetised metric, 
whereas the DALYs and QALYs have not initially been 
monetised. For example, the WTP includes all the private 
costs, whereas the DALYs and QALYs cover only the indi-
vidual borne intangible costs (Fig. 1) (Hofstetter and Ham-
mitt 2002). Hence, it is of great importance to be aware of 
the included health benefit aspects and of the impact that the 
choice of health valuation method has on CBA as decision 
support.
The specific aims of this paper were to: identify health 
valuation methods related to gastrointestinal illnesses; 
map the health valuation methods in relation to the health 
benefit aspects presented in Fig. 1 and to assess the effect 
Fig. 1  Avoided costs related 
to health benefits relevant for 
environmental decision mak-
ing, adopted and adjusted from 
Seethaler (1999) and Hofstetter 
and Hammitt (2002). Note that 
from a risk management per-
spective, these costs are in fact 
benefits when the health risks 
are reduced
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of different health valuation methods when applied in 
CBA as decision support for microbial risk mitigation 
measures in a drinking water system. More precisely, in 
a case study, we investigated if changing the health valu-
ation method could change the rank order of the decision 
alternatives’ NPVs. It should be noted that the intention 
of this paper was not to fully review all health valuation 
methods, but rather to illustrate and describe a wide range 
of methods that are available for monetising health ben-
efits to provide input for CBA.
Methods
First, a literature review was performed to identify meth-
ods for economic valuation of gastrointestinal illness. 
Second, the identified methods were applied in a case 
study using a risk-based decision model to prioritise 
microbial risk mitigation measures in a drinking water 
system. The case study is reported in a separate chapter.
The literature review of health valuation methods was 
conducted using an approach suggested by Gyllensvärd 
(2010), although adjusted to be suitable for a method 
review. The strategy was to identify literature that: esti-
mated the WTP for avoiding gastrointestinal/foodborne 
disease/illness; applied COI approaches in CBA studies; 
estimated the monetary value of a DALY/QALY; esti-
mated the societal monetary value of a DALY/QALY; or 
provided/applied other type of health valuation methods 
in the context of CBA. Scopus and Web of Science Core 
Collection were primarily used for acquiring references.
Various combinations of the words/strings were used: 
“economic valuation”, “stated preferences”, “revealed 
preferences”, “cost of illness”, “health effects”, “quality 
adjusted life years”, “disability adjusted life years”, “gas-
trointestinal disease”, “foodborne illness”, “pathogen”, 
“water quality”, “drinking water quality”, “microbial 
water quality”, “decision support”, “decision making”, 
“decision model”, “cost–benefit analysis” and “bene-
fit–cost–analysis”. Additionally, reference lists in relevant 
literature were scrutinised to acquire more information.
Inclusion criteria were that the study provided either 
a clear description of the health benefits included in the 
CBA or that the health benefits were monetised. In total, 
84 studies were listed and graded using the scale relevant, 
possibly relevant and irrelevant. When a health valua-
tion method was identified, further search strings for that 
specific method were used. In this expanded search, also 
grey literature was considered. Studies related to air pol-
lution were excluded since the focus was on waterborne 
gastrointestinal illnesses.
Results
In this section, we first list the identified health valuation 
methods (Table 1) and relate them to the health benefit 
aspects described in Fig. 1. We then describe each method 
and relate it to CBA and the different health benefit aspects 
in more detail. Note that the list does not claim to be com-
plete, but rather comprises the methods that are possible to 
apply in a risk-based CBA and are of interest to use in the 
previously developed decision model (Bergion et al. 2018) 
for drinking water applications. Even so, the identified 
methods can be valid for other decision models as well.
WTP for avoiding a certain state of illness can be elic-
ited using both stated preferences and revealed prefer-
ence methods (Andersson et al. 2016; Birol et al. 2006). 
Choice experiments have been used for estimating the 
WTP for health risk reduction in water for Campylobacter 
(Andersson et al. 2016), and contingent valuation method 
and choice experiment were used for general microbial 
risks (Adamowicz et al. 2011). The WTP for avoiding a 
case of campylobacteriosis was estimated to SEK (year 
2016) 490,000 (SEK 499,800, year 2017) (Andersson et al. 
2016), for avoiding general microbial illness Can$ (year 
2004) 24,000–28,000 (SEK 182,160–212,520, year 2017) 
(Adamowicz et al. 2011), and for avoiding gastrointestinal 
disease US$ (year 2012) 1752 (SEK 15,339, year 2017) 
(Viscusi et al. 2012).
COI of a specific pathogen can be used as a proxy for 
WTP (Mangen et al. 2010). COI generally includes cost 
for healthcare, cost for production loss and some stud-
ies also include the cost of premature fatalities in various 
ways (Rice et al. 2006). A recent paper summarised COI in 
Sweden for five foodborne pathogens; a case of campylo-
bacteriosis was estimated to cost € (year 2016) 979 (SEK 
9586, year 2017) (Sundström 2018).
COI + includes COI and adds disutility using various 
methods. COI has been complemented with WTP (Lvo-
vsky et  al. 2000; Mangen et  al. 2010) and/or QALY/
DALY (Mangen et al. 2010; Scharff 2012) to make sure 
that additional health benefit aspects are considered. Nev-
ertheless, it is essential not to double count any costs (Lvo-
vsky et al. 2000). Minor et al. (2015) reported the aver-
age cost of foodborne illness to be US$ (year 2013) 3630 
(SEK 31,781, year 2017) per case in the United States; the 
analysis included all aspects of COI and also accounted 
for disutility of being ill by monetising a QALY. Hoff-
mann et al. (2012) included premature death estimate in 
their COI for different foodborne illness, using a value 
of a statistical life. In Sweden, a CBA was performed for 
investing in ultrafiltration treatment for increased drink-
ing water quality; the health benefits were accounted for 
using a COI + approach including medical and production 
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costs of illness and adding disutility using a unit cost per 
day (WSP 2010). The disutility was based on findings by 
Ready et al. (2004).
The value of a DALY (VoD) has been estimated using, 
for example, human capital approach (using gross domestic 
product to estimate loss of production) (WHO 2001) and 
friction cost method (Mangen et al. 2005). Measures for 
health risk reduction have been assessed to be cost-effective 
if they result in a cost per avoided DALY of one to three 
times the per capita gross domestic product (Robinson et al. 
2016; WHO 2001). It should be noted that estimating the 
VoD using the human capital approach does not include the 
individual borne intangible costs.
The value of a QALY (VoQ) was early described for food-
borne illness by Mauskopf and French (1991); the health 
benefits in terms of increased QALYs were multiplied by a 
unit value for one QALY. Two main approaches to estimate 
the value of a QALY are to either elicit the WTP directly 
or to estimate the WTP based on value of a statistical life 
(Andersson et al. 2015). A recent review (Svensson et al. 
2015) of literature estimating the WTP for a QALY reported 
a wide spectrum of QALY valuations ranging from < €10,00 
to €4,800,000 (SEK 10,176–48,844,800, year 2017). The 
wide range is explained by the fact that each study differs 
in methodology, elicitation method, geography, social/indi-
vidual perspective, etc. If studies are based on health metrics 
including aspects of loss of production, then the health bene-
fit aspects of individual costs of illness can also be included, 
as indicated by the striped cells in Table 1.
The societal value of a DALY (SVoD) was estimated 
based on disbursement of means from the Global Fund for 
AIDS, Tuberculosis and Malaria (Brent 2011). These esti-
mates can be interpreted as a revealed preference method for 
estimating the societal WTP for avoiding one DALY.
In the context of the societal value of a QALY (SVoQ), 
Bobinac et al. (2010) suggested three possible methods 
for estimating the threshold for cost-effective healthcare 
improvements: institutional decisions, budget constraints 
and the marginal societal value of health. For estimating the 
cost-effectiveness of healthcare improvements, thresholds of 
cost per QALY have been established in several countries. 
In Sweden, the National Board of Health and Welfare has 
provided a threshold of SEK 500,000 per QALY (NBHW 
2015). Svensson et al. (2015) have suggested a high (SEK 
Table 1  Description of the identified health valuation methods
The illustrations in the rightmost column refer to the different aspects of health benefits described in Fig. 1
a Examples of references that describe or use the methods: WTP (Andersson et al. 2016); COI (Scharff 2012; Sundström 2018); COI + (Minor 
et al. 2015; Scharff 2012); VoD (Robinson et al. 2016; WHO 2001); VoQ (Ryen and Svensson 2015); SVoD (Brent 2011); SVoQ (Svensson et al. 
2015)
b Quality adjusted life years (QALY), disability adjusted life years (DALY), value of a statistical life (VSL), revealed preferences (RP), stated 
preferences (SP) and Global Fund for AIDS, Tuberculosis and Malaria
c The boxes shaded in grey are referring to the included benefits illustrated in Fig.  1. Striped boxes indicate that the boxes can be included 
depending on the study forming the base of the valuation
Methoda Abbreviation Descriptionb Aspects of health 
benefits  includedc
Willingness to pay WTP Estimates a person’s WTP to avoid a certain health state
Cost of illness COI Established approach to estimate costs of illness; sometimes referred to as a mini-
mum WTP
COI + Disutility COI+ Cost of illness and part of disutility added using QALY/DALY/VSL or other 
approaches
Value of a DALY VoD Based on cost-effectiveness thresholds for decisions related to global health.
Value of a QALY VoQ Based on a review of WTP for a QALY, either from direct SP estimations or by 
converting VSL estimates
Societal value of a DALY SVoD Societal value of a DALY was estimated using RP from grant decisions from the 
GFATM
Societal value of a QALY SVoQ Reimbursement decisions for pharmaceuticals were used to estimate the societal 
WTP for a QALY
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1,256,600, year 2017) and a low (SEK 721,000, year 2017) 
implied societal WTP for a QALY, based on pharmaceutical 
reimbursement decisions; this study states that the estimate 
incorporates all costs, including costs beyond the healthcare 
sector.
Case Study
In this section, the case study is described; more informa-
tion regarding the case study and detailed description of the 
risk-based decision model can be found in Bergion et al. 
(2018). For the case study, we chose the Vomb drinking 
water system that provides drinking water to approximately 
330,000 consumers in the south of Sweden. High density of 
on-site wastewater treatment systems (OWTSs), wastewater 
overflows and grazing animals in the catchment of the water 
source Lake Vomb were identified as risk sources. The case 
study focused on comparing alternatives for risk mitiga-
tion aimed at reducing the microbial risks. Three mitigation 
alternatives (A1–3) were connecting 25, 50 and 75% of the 
OWTSs to a wastewater treatment plant that discharges the 
effluent to a non-drinking water recipient. A fourth mitiga-
tion alternative (A4) was installing a UV disinfection step 
in the drinking water treatment plant. In the risk-based 
decision model, hydrodynamic modelling and QMRA were 
used to calculate the annual number of avoided infections 
for each mitigation alternative. In this case study, Campylo-
bacter, norovirus and Cryptosporidium were used as refer-
ence pathogens, representing the pathogen groups, bacteria, 
viruses and protozoa respectively. The avoided cases were 
monetised and included in a CBA to compare the mitigation 
alternatives. Monte Carlo simulations (10,000 iterations) 
were used throughout the model to include uncertainties.
Health benefits were expressed as avoided infections with 
each pathogen. The reduced infections (RI) were expressed 
as:
where P was the reduction in annual probability of infection 
for reference pathogen i and C was the number of drinking 
water consumers supplied with water from the Vomb drink-
ing water treatment plant. It was conservatively assumed 
that all infections resulted in illness. The reduction in annual 
probability of infection for Campylobacter, norovirus and 
Cryptosporidium were calculated in our earlier study (Ber-
gion et al. 2018) and are summarised in Table 3 in Appen-
dix. The number of consumers was assumed to be 330,000 
in the year 2016. The projected population growth of 30% 
by the year 2060 (Statistics Sweden 2018b) was recalculated 
into an annual population growth used throughout the time 
horizon. The number of consumers in the end of the 100-
year time horizon was thus 560,000.
(1)RI = Pi ⋅ C
The health benefits were monetised using the identified 
health valuation methods (Table 1) for each reference patho-
gen. Monetary values were expressed in SEK recalculated to 
their value in the year 2017 (Statistics Sweden 2018c) and 
using the average exchange rates for 2017 of SEK 8.5, 6.6 
and 9.6 for $US, $Can and €, respectively (Sveriges Riks-
bank 2018). The adopted values for different illnesses are also 
reported in Table 4 in the appendix. For monetising the health 
benefits, the general equation was:
where BH_j was the monetary value of the health benefit, 
mj(RI) was a function describing the value of avoiding an 
illness when using the health valuation method j.
For willingness to pay (WTP), the following equation was 
used:
WTP was SEK 499,800; 29,224 and 111,420 for Campylo-
bacter (Andersson et al. 2016), norovirus and Cryptosporid-
ium, respectively. For norovirus and Cryptosporidium, the 
WTP was estimated using the WTP for avoiding Campylobac-
ter and adjusted using the ratio of the loss of QALY between 
Norovirus and Campylobacter (17.4), and Cryptosporidium 
and Campylobacter (4.5), respectively.
For cost of illness (COI), the following equation was used:
COI was SEK 9586; 4775 and 18,525 Campylobacter 
(Sundström 2018), norovirus (Scharff 2012) and Crypto-
sporidium (Scharff 2012), respectively.
For cost of illness + disutility (COI + D), the following 
equation was used:
COI + D was SEK 30,537; 6064 and 26,273 for Campy-
lobacter (Minor et al. 2015), norovirus (Scharff 2012) and 
Cryptosporidium (Scharff 2012), respectively.
For value of a DALY (VoD), the following equation was 
used:
where Di was the amount of DALYs gained if an illness 
with pathogen i was avoided. VoD was the Swedish gross 
domestic product per capita (SEK 457,000) for the year 2017 
multiplied by three (Statistics Sweden 2018a). Di was set to 
be 0.00328, 0.000716 and 0.00267 DALYs for Campylo-
bacter, norovirus and Cryptosporidium, respectively, based 
on the QMRA-tool developed for Swedish drinking water 
producers (Abrahamsson et al. 2009).
For value of a QALY (VoQ), the following equation was 
used:
(2)BH_j = mj(RI)
(3)BH_WTP =WTPi ⋅ RI
(4)BH_COI = COIi ⋅ RI
(5)BH_COI+D = (COI + D)i ⋅ RI
(6)BH_VoD = VoD ⋅ Di ⋅ RI
(7)BH_VoQ = VoQ ⋅ Qi ⋅ RI
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where Qi was the amount of QALYs gained if an illness with 
pathogen i was avoided. VoQ was the mean value reported 
by Ryen and Svensson (2015). Qi was assumed to be 0.0157, 
0.0009 and 0.0035 QALYs for Campylobacter, norovirus 
and Cryptosporidium, respectively (Batz et al. 2014).
For societal value of a DALY (SVoD), the following 
equation was used:
SVoD was SEK 61,583 based on Brent (2011).
For societal value of a QALY (SVoQ), the following 
equation was used:
SVoQ was SEK 1,256,600 based on the high estimate 
of societal WTP for a QALY reported by Svensson et al. 
(2015).
The environmental benefits for mitigation alternatives 
A1–3 were identified as reduced nutrient load to the recipi-
ent, due to increased removal of phosphorous and nitrogen 
in the wastewater treatment plant. For A4, no environmental 
benefits were identified. The total benefits (B) were calcu-
lated as:
where BH_i were the health benefits and BE were the envi-
ronmental benefits.
The net present value (NPV) was calculated as:
where B and C were the monetised benefits (SEK) and costs 
(SEK) for each year t during the time horizon T (years), and 
r (%) was the discount rate. The costs and further details 
regarding the environmental benefits for each mitigation 
alternative were presented in Bergion et al. (2018).
In Sweden, there are no guidelines on what discount rate 
to choose when performing a societal CBA for reducing 
microbial risks. In this study, a discount rate of 3.5% was 
chosen, as suggested by the Swedish Transport Administra-
tion when performing societal CBA for large infrastructure 
projects (STA 2016). For sensitivity analysis, a discount rate 
(8)BH_SVoD = SVoD ⋅ Di ⋅ RI
(9)BH_SVoQ = SVoQ ⋅ Qi ⋅ RI















of 1% was applied. Using a lower discount rate in economic 
analyses concerning long time horizons and future genera-
tions have been extensively described (e.g. Boardman et al. 
2011). A time horizon of 100 years was used. As a sensitiv-
ity analysis, a time horizon of 50 years was also included. 
The rank order of the mitigation alternative was calculated 
based on the expected NPV.
The risk reduction was expressed as avoided annual cases 
of illnesses with reference pathogens (Table 2) calculated by 
combining the reduced annual probability of infection with 
the number of drinking water consumers, conservatively 
assuming that all infections result in illness.
The total benefits for each mitigation alternative calcu-
lated using the identified health valuation methods are pre-
sented (Fig. 2).
The division of the total benefits between the health and 
environmental benefits varied depending on the health valu-
ation method (Fig. 2). It is clear that the WTP method gen-
erates substantially larger benefits than the other methods.
The rank orders of the NPVs for the risk mitigation alter-
natives are presented in Fig. 3.
The rank order of the NPV varied depending on the 
health valuation method for WTP, COI and COI + , but not 
for VoD, VoQ, SVoD and SVoQ (Fig. 3). A3 was the alterna-
tive with the lowest rank. A4 had the highest ranking when 
using WTP, indicating that when health benefits were valued 
at a higher level, the most societally beneficial alternative 
changed from A1 to A4. The rank order also varied depend-
ing on the time horizon and/or the discount rate. Going 
from 3.5% to 1% discount rate increased the rank of A2 and 
decreased the rank of A1 and A4 depending on which valu-
ation method applied. Using a longer time horizon promoted 
A4 for the valuation methods COI and COI + when looking 
at the 1% discount rate but only for COI when looking at the 
3.5% discount rate. Front loaded risk reduction measures, 
i.e. when investment costs occur in the beginning, get higher 
rank if low discount rates and long time horizons are used, 
since a higher value is assigned to the benefits that occur in 
the future relative if a higher discount rate is used. A low 
discount rate and a long time horizon favoured the mitiga-
tion alternative A2 resulting in an increase in rank order for 
the valuation method WTP, whereas the other mitigation 
Table 2  Avoided annual cases (5th, 50th and 95th percentiles) for the reference pathogens Campylobacter (Campy), norovirus (Noro) and 
Cryptosporidium (Crypto) for the risk mitigation alternatives A1–4
A1 A2 A3 A4
P05 P50 P95 P05 P50 P95 P05 P50 P95 P05 P50 P95
Campy 8.3E−3 5.2E−2 7.2E−1 1.6E−2 9.7E−2 1.3E + 0 2.3E−2 1.4E−1 1.9E + 0 4.1E−2 2.5E−1 3.4E + 0
Noro 2.2E + 0 9.3E + 0 5.0E + 1 4.5E + 0 1.9E + 1 1.0E + 2 6.8E + 0 2.8E + 1 1.5E + 2 1.2E + 1 5.1E + 1 2.7E + 2
Crypto 9.1E−5 3.5E−4 1.4E−3 1.8E−4 7.0E−4 2.7E−3 2.7E−4 1.1E−3 4.1E−3 4.8E−4 1.9E−3 7.2E−3
105Economic Valuation for Cost–Benefit Analysis of Health Risk Reduction in Drinking Water Systems 
1 3
alternatives kept their rank (A3) or lowered their rank (A1 
and A4).
Discussion
Different methods can be used to support decisions on how 
to mitigate health risk in drinking water supplies. Methods 
such as multi criteria decision analysis and cost-effective-
ness analysis do not require a monetisation of health effects. 
However, there are benefits of monetising health effects 
since it, for example, clarifies the societal benefits of imple-
menting mitigation measures and thus provides useful deci-
sion support. The question of which health valuation method 
to use, is not straightforward to answer, as it depends on 
the purpose and the context of the decision. Mangen et al. 
(2010) suggested that COI + (a combination of COI and 
WTP, or COI and DALYs/QALYs) can be used to describe 
health burden when prioritising foodborne risk mitigation. 
Cookson (2003) saw a possibility to use WTP for resource 
allocation between different societal sectors (water, traffic, 
agriculture, etc.). The use of a societal WTP for avoiding a 
QALY (Svensson et al. 2015) or a DALY (Brent 2011) is 
another approach.
The importance of the societal aspect has been empha-
sised when quantifying health effects for decision making 
(Bobinac et al. 2013; Shiroiwa et al. 2010). Several stud-
ies of the WTP for a QALY showed that the level of WTP 
for your own health, family health or health in society dif-
fered (Hammitt and Haninger 2017; Shiroiwa et al. 2010). 
In UK, US and Australia, the WTP for societal health was 
higher than the WTP for improving personal health (Shi-
roiwa et al. 2010). This implies that the valuation of health 
reaches beyond the individual perspective, and it has been 
suggested to use a societal WTP for a QALY in economic 
assessments (e.g. Whitehead and Ali 2010).
Fig. 2  Total benefits (mean 
value) for the risk mitigation 
alternatives (A1–4), using dif-
ferent health valuation methods 
(WTP, COI, COI + , VoD, VoQ, 
SVoD and SVoQ). The division 
between the health (dark grey) 
and environmental (light grey) 
benefits is illustrated. A time 
horizon of 100 years and a 
discount rate of 3.5% were used. 
For abbreviations see Table 1
Fig. 3  Rank order of the NPVs 
(mean value) of the mitigation 
alternatives (A1-4) using dif-
ferent health valuation methods 
(WTP, COI, COI + , VoD, VoQ, 
SVoD and SVoQ). The results 
are shown for time horizons 
of 100 (a and b) and 50 years 
(c and d) as well as discount 
rates of 3.5 (a and c) and 1% (b 
and d). For abbreviations see 
Table 1
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Using a SVoD or a SVoQ, from a societal point of view, 
includes all aspects of the health risk reduction. Adopting a 
societal rather than individual point of view can also account 
for altruistic effects (Adamowicz et al. 2011). Four issues 
were identified that have implications for estimating the 
societal value of a QALY (Smith and Richardson 2005): Is 
societal WTP the sum of individual’s WTP?; Will individual 
WPT map directly to societal WTP?; Is personal income the 
appropriate budget constrain?; Should we adjust WTP for 
ability to pay?. These issues need to be recognised in order 
to transfer individual WTP methods for valuing QALYs into 
societal WTP for QALYs to be used in decision making. 
Nevertheless, aggregating individual WTP can be one of 
several possible ways to estimate the societal WTP and is 
closely related to a utilitarian approach (Smith and Richard-
son 2005). The societal WTP for avoiding a DALY would 
provide some kind of a lowest value of a DALY (Brent 
2011). This is because there is a public consensus that not 
enough resources were put into preventing these diseases, 
and that the grants provided from the Global Fund for AIDS, 
Tuberculosis and Malaria were made under strict budget 
constraints (Brent 2011). Therefore, if more money would 
be available, larger investments would have been possible, 
and the societal WTP for a DALY would be higher.
WTP for avoiding specific health states, or for general 
health improvements, has been criticised, since it can be 
affected by individual income level and thus promoting 
health interventions that are targeted towards health risk 
reductions in wealthy parts of society (Polyzou et al. 2011; 
SBU 2014). From a healthcare perspective, WTP was 
described to be inappropriate for estimating the economic 
value of an intervention, since in the estimates based on con-
tingent valuation method or choice experiments, respondents 
tend to be insensitive to the magnitude of health improve-
ments and the duration of illness (Haninger and Hammitt 
2011), and the valuation of the specific intervention being 
surveyed is exaggerated (Cookson 2003). WTP for avoid-
ing an illness has been assessed to diminish with increasing 
duration of illness (Reed Johnson et al. 1997; Van Hout-
ven et al. 2006). Increasing severity has been shown to both 
increase the WTP (Reed Johnson et al. 1997; Van Hout-
ven et al. 2006) and to decrease the WTP (Cookson 2003; 
Haninger and Hammitt 2011). Thus, using a case specific 
WTP would be preferred.
Looking at the QALY value, or the WTP for avoiding a 
QALY, there are similar concerns as for the WTP for avoid-
ing a specific health state. If QALY values are based on a 
questionnaire on prolonged life (value of a statistical life) 
rather than increased life quality, the QALY value will be 
higher (Ryen and Svensson 2015). Furthermore, studies 
investigating the WTP for small changes in QALYs often 
render a larger WTP compared to when larger changes in 
QALYs are investigated (Haninger and Hammitt 2011; 
Ryen and Svensson 2015). Hence, the issue of “a QALY is a 
QALY is a QALY” (i.e. whether a QALY is the same regard-
less of other factors such as the cause of disease, severity, 
length of illness, etc.) is once again highlighted (Ryen and 
Svensson 2015).
In the case study, the choice of health valuation methods 
was shown to change the rank order of the risk mitigation 
alternatives. These results indicate that decision makers 
need to be aware of the health valuation method used and 
of the health benefit aspects included. When using the WTP 
method, alternative A4 is ranked as number one, since it 
was the mitigation alternative with the highest health risk 
reduction. The case study only included health benefits and 
environmental benefits, omitting any additional benefits 
that can be related to water quality improvements (Hutton 
2001) (e.g. better productivity/products related to industry, 
aquaculture, agriculture; and improved animal health). The 
relative importance between the health and environmental 
benefits was shown to change depending on the health valu-
ation method. The approach here was to include investment, 
maintenance and reinvestment costs. However, the reinvest-
ment costs are only partly considered. Especially, for the UV 
treatment, a more comprehensive approach could be used. 
In this type of model, it may also be important to define 
terminal values since these and reinvestments may affect 
the outcome of the model. Hence, depending on the main 
reason for implementing the risk reduction measure and their 
characteristics, the decision makers need to be aware of the 
relative importance of health and environmental benefits, as 
well as of reinvestments and terminal values.
The results of this study promote the use of a SVoQ or 
SVoD when applying health valuation methods in a societal 
CBA for preparing decision support in a drinking water sys-
tem. This is also valid in other types of contexts in which 
it is important to include all of the health benefit aspects. 
Using SVoQ or SVoD helps avoiding double counting of 
health benefit aspects. Nevertheless, using a unit value for a 
SVoQ or SVoD makes it difficult to distinguish the contribu-
tion from each aspect. If separation of different aspects is of 
importance, a COI or COI + approach allows for the different 
aspects to be described in detail. It is also possible to use a 
combination of COI and VoQ or VoD, but combining several 
methods makes it important not to double count any of the 
health benefit aspects.
In the study by WSP (2010) on the societal profitabil-
ity of installing ultrafiltration in a drinking water treatment 
plant, the daily cost for disutility was based on the report 
(SNIER 2009), which in turn was based on Ready et al. 
(2004). Ready et al. (2004) performed a stated preference 
study of avoiding the health outcome described as “One day 
of persistent nausea and headache with occasional vomit-
ing… (the) patient is unable to go to work or leave the home, 
but domestic chores are possible.” This description indicates 
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that the study participants were expected to include their loss 
of production in the response. It is thus unclear whether the 
approach by WSP (2010) double counts part of the health 
benefits, since the cost of illness (production) was accounted 
for separately, and the study (Ready et al. 2004) used for 
estimating the cost of disutility also could have included 
parts of the production loss, depending on how exactly the 
survey was conducted and how the respondents interpreted 
the health outcome description. The original questionnaires 
from the study by Ready et al. (2004) were not available to 
be scrutinised. This issue illustrates the difficulty of compar-
ing and transferring results from stated preference studies 
and further emphasises the importance of being aware of 
the different health benefit aspects (Fig. 1).
It has been shown that it is preferred to reduce health 
risks related to drinking water compared to foodborne health 
risks, because the latter are easier to control (Andersson 
et al. 2016); one can choose which food to buy unlike the 
drinking water delivered to the tap. Additionally, if a DALY 
was caused by HIV or AIDS, the value of that DALY was 
higher compared to the other studied illnesses (Tuberculosis 
and Malaria) (Brent 2011). Given that the health valuation 
is affected by the cause of the health impairment, there is 
a need for further research to establish common methods 
for health benefit valuation, overarching different contexts 
and societal sectors (water, food, traffic, etc.), while at the 
same time acknowledging their heterogeneity. The question 
of how health valuation over time should be integrated into 
CBA needs to be addressed. One option could be to use a 
non-linear function to estimate the value of health. CBA 
facilitates the inclusion of health benefits as part of a holistic 
decision support, in which other, non-health, effects (e.g. 
supply interruption, aesthetic benefits) can also be included. 
Thus, CBA helps drinking water producers to allocate 
resources for risk reduction measures directed towards the 
most relevant type of risk (e.g. health risks, supply interrup-
tion, etc.). Additionally, CBA allows for comparison of risk 
reduction measures overarching several sectors, optimising 
the use of societal resources.
Conclusions
Based on the review of the health valuation methods and 
the results of the case study, the following main conclusions 
were drawn:
• Seven health valuation methods were identified: will-
ingness to pay, cost of illness, cost of illness + disutility, 
value of a disability adjusted life year, value of a quality 
adjusted life year, societal value of a disability adjusted 
live year and societal value of a quality adjusted live year. 
The rank order of the risk mitigation alternatives with 
respect to their net present values may differ depending 
on the health valuation method.
• A low discount rate and a long time horizon favours miti-
gation alternatives with benefits that occur in the future.
• In CBA for decision support in the drinking water con-
text, it is important to include all health benefit aspects. 
The most comprehensive currently available valuation 
methods to include all aspects of health benefits are the 
societal value of a quality adjusted life year or of a dis-
ability adjusted life year.
• If the choice of health valuation method is ambiguous, 
a sensitivity analysis of the health valuation methods 
should be performed in order to provide adequate deci-
sion support.
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Appendix
Reduction in probability of infection with each reference 
pathogen in each risk mitigation alternative is reported in 
Table 3.
The cost for one illness with each reference pathogen is 
reported in Table 4.
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